Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

TheMotleyFool

0 0

Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

Biotech investors are probably a little depressed, with valuations of the industry down since their peak in February. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights explain why smaller development-stage companies have been hit especially hard during the downturn.

Source Fool.com

Like: 0

NVAX

Share